文献速递中医内科中药与中成药合理使用

中药辅助治疗多发性硬化急性复发期的系统评价与Meta分析

Chinese herbal medicine adjunct therapy in patients with acute relapse of multiple sclerosis: A systematic review and meta-analysis.
PubMed 文献 · Complement Ther Med · 2017-02-21

该系统评价纳入20项随机对照试验共1100例多发性硬化急性复发期患者,评估中药辅助治疗的疗效与安全性。Meta分析显示,与常规西药治疗相比,中药在改善扩展残疾状态评分、年复发频率、年复发率、年复发间隔及总临床有效率方面均有显著效果(P<0.01)。但因方法学质量差和临床异质性,证据有限,尚不能推荐常规使用。

要点

  • 中药辅助治疗可显著改善多发性硬化急性复发期患者的扩展残疾状态评分(P<0.01)。
  • 中药辅助治疗在降低年复发频率、年复发率及延长年复发间隔方面优于常规西药(P<0.01)。
  • 证据方法学质量差且存在临床异质性,尚不能推荐常规使用中药辅助治疗。

核心结论

  • 现有证据支持但有限地推荐中药辅助治疗用于多发性硬化,因方法学质量差和临床异质性,需进一步严格随机对照试验验证。

研究设计与样本

  • 系统评价与Meta分析,检索6个数据库,纳入2004年至2015年的20项随机对照试验,共1100例多发性硬化急性复发期患者。
  • 采用Cochrane Back Review Group推荐的12条标准评估偏倚风险。

主要发现

  • 与常规西药治疗相比,中药辅助治疗在改善扩展残疾状态评分方面有显著效果(P<0.01)。
  • 中药辅助治疗在改善年复发频率方面有显著效果(P<0.01)。
  • 中药辅助治疗在提高总临床有效率方面有显著效果(P<0.01)。
  • 中药辅助治疗在年复发率和年复发间隔分析中与常规西药治疗有显著差异(P<0.01)。
  • 6项研究监测了不良反应,所有多发性硬化患者对中药辅助治疗耐受良好。

关键数值与推荐

  • 高频使用中药筛选标准为累积频率超过50%。
  • 使用频率最高的前5味中药依次为当归、甘草、赤芍、熟地黄和僵蚕。
  • 偏倚风险符合标准的数量在5/12至7/12之间。

临床怎么用

  • 中药可作为多发性硬化急性复发期的辅助治疗选择,但需结合方法学质量和临床异质性谨慎评估。
  • 高频使用中药(当归、甘草、赤芍、熟地黄、僵蚕)可作为进一步临床应用和临床试验的候选药物。

局限性

  • 纳入研究的方法学质量差。
  • 存在临床异质性。
  • 需要进一步严格的随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients with multiple sclerosis (MS) resort to complementary and alternative medicine, which is used in 33%-80% of MS patients in the developed country. The purpose of this study is to assess the efficacy and safety of Chinese herbal medicine (CHM) as an adjunct therapy of patients with acute relapse of MS. METHODS: Six databases were searched for randomized-controlled trial of CHM for acute relapse of MS. The risk of bias was assessed by using the twelve criteria recommended by the Cochrane Back Review Group. The primary outcome measures of interest are the Expanded Disability Status Score, annual relapse frequency, annual relapse rate, and annual relapse interval. The secondary outcome measures are the clinical efficacy rate and adverse events. The selection criteria of high-frequency herbs for MS are those with cumulative frequency over 50%. We analyzed the data using Review Manager (version 5.3). RESULTS: A total of 1100 participants were included in the 20 studies from 2004 to 2015. The number of risk of bias which met the criteria varied from 5/12 to 7/12. The top 5 most frequently used herbs are ordinally Radix Angelicae Sinensis, Radix Glycyrrhizae, Radix Paeoniae Rubra, Radix Rehmanniae Preparata, and Bombyx Batryticatus. The meta-analysis showed a significant effect of CHM for improving Expanded Disability Status Score (P<0.01), annual relapse frequency (P<0.01) and the total clinical efficacy rate (P<0.01) compared with western conventional treatment. In analysis of annual relapse rate and annual relapse interval, there was a significant difference between CHMs and western conventional treatment (P<0.01). Adverse effects were monitored in 6 studies, and were well tolerated in all MS patients. CONCLUSIONS: The available evidence from present study supported but limited to recommend the routine use of CHM adjuvant therapy for MS because of the poor methodological quality and clinical heterogeneity. However, we identified an area that is worthy of further study. Furthermore, we selected high frequent use of CHMs as a promising candidate for further clinical application and MS trials. Further rigorous randomized-controlled trials are needed.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Song L, Zhou QH, Wang HL, et al. Chinese herbal medicine adjunct therapy in patients with acute relapse of multiple sclerosis: A systematic review and meta-analysis. Complement Ther Med. 2017. PMID: 28434474. doi:10.1016/j.ctim.2017.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。